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Abstract: Background and objectives:Although studies have elucidated the significant biomedical potential
of biogenic metallic nanoparticles (MNPs), it is very important to explore the hazards associated with
the use of biogenic MNPs. Evidence indicates that genetic toxicity causes mutation, carcinogenesis, and
cell death. Materials and Methods: Therefore, we systematically review original studies that investigated
the genotoxic effect of biologically synthesized MNPs via in vitro and in vivo models. Articles were
systematically collected by screening the literature published online in the following databases; Cochrane,
Web of Science, PubMed, Scopus, Science Direct, ProQuest, and EBSCO. Results: Most of the studies
were carried out on the MCF-7 cancer cell line and phytosynthesis was the general approach to
MNP preparation in all studies. Fungi were the second most predominant resource applied for MNP
synthesis. A total of 80.57% of the studies synthesized biogenic MNPs with sizes below 50 nm. The
genotoxicity of Ag, Au, ZnO, TiO2, Se, Cu, Pt, Zn, Ag-Au, CdS, Fe3O4, Tb2O3, and Si-Ag NPs was
evaluated. AgNPs, prepared in 68.79% of studies, and AuNPs, prepared in 12.76%, were the two most
predominant biogenic MNPs synthesized and evaluated in the included articles. Conclusions: Although
several studies reported the antigenotoxic influence of biogenic MNPs, most of them reported biogenic
MNP genotoxicity at specific concentrations and with a dose or time dependence. To the best of our
knowledge, this is the first study to systematically evaluate the genotoxicity of biologically synthesized
MNPs and provide a valuable summary of genotoxicity data. In conclusion, our study implied that
the genotoxicity of biologically synthesized MNPs varies case-by-case and highly dependent on the
synthesis parameters, biological source, applied assay, etc. The gathered data are required for the
translation of these nanoproducts from research laboratories to the clinical market.
Keywords: genotoxicity; biosynthesis; metal nanoparticles; systematic review
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1. Introduction
Nanotechnology is a multidisciplinary and interdisciplinary science that can be defined as the
design, synthesis, and application of materials and devices at the nanolevel in different areas, including
medicine, biology, physics, chemistry, and engineering [1,2]. Different types of nanomaterials with a
wide range of size and shape have been exploited in different fields of biomedicine such as drug delivery
and imaging (Figure 1). The global nanotechnology industry is anticipated to reach US $75.8 billion by
2020 [3]. The synthesis of metal nanoparticles (MNPs) is an emerging area of interest in nanoscience
due to their unique physical, chemical, electrical, and optical properties compared to those of the bulk
material [2]. The global sale of MNPs is anticipated to reach US $50 billion by 2026 [4]. Generally, there
are two approaches to the synthesis of MNPs: the top-down approach and the bottom-up approach.
A schematic of these approaches is shown in Figure 2. In the top-down approach, MNPs are synthesized
by cutting the bulk material via different mechanical procedures to produce nanosized structures. In the
bottom-up approach, MNPs are synthesized at the molecular level via different chemical or biological
procedures [3,5]. Among the physical, chemical, and biological methods for MNP synthesis, the biological
methods are bottom-up approaches that overcome some of the unsatisfactory conditions of the physical
and chemical methods (e.g., high energy or temperature requirements, hazardous waste generation, and
toxic chemical use) [6–8]. Nanobiotechnology studies are categorized as “Gold Biotechnology” studies
and involve the synthesis of MNPs by exploiting biological sources [7]. A number of plants [7,9–11],
algae [12,13], fungi [14], and bacteria [15,16] have been reported to biosynthesize MNPs as ecofriendly,
biocompatible, and inexpensive alternatives to conventional physical and chemical methods. Notably,
MNPs have been used in wound dressings, cell labeling, photoimaging, sensors, drug delivery, gene
delivery, photothermal therapy, etc. [7]. Additionally, a recent 2018 meta-analysis reported that the
cytotoxicity of biogenic MNPs in cancer cell lines was 9 times higher than that in normal cell lines,
indicating much greater MNP cytotoxicity in cancer cell lines (OR = 9.004, p < 0.001) [16]. Although
studies have elucidated the significant biomedical and pharmaceutical potential of biogenic MNPs,
exploring the hazards associated with the use of biogenic MNPs is very important. The large surface
area, high cellular penetration ability, and significant catalytic activity of MNPs may result in MNPs
having greater toxicity than their bulk counterparts [17].
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Genotoxicity is a concern associated with the use of MNPs because it plays a major role in
the initiation and progression of abnormalities. Genotoxicity can be defined as destructive genetic
alterations involving gene mutations, structural chromosomal aberrations, and recombination that
are induced by genotoxins [17–19]. Genotoxins are agents that can damage the DNA sequence and
chromosomal structure by addition, deletion, duplication, ring formation, etc. Genotoxins are classified
into three groups on the basis of their effects: (a) carcinogens or cancer-causing agents, (b) mutagens or
mutation-causing agents, and (c) teratogens or birth-defect-causing agents [20]. Registering a new
drug without performing genotoxicity assays is impossible. In 1984, the Ministry of Health and Welfare
(MHW) of Japan adopted the use of genotoxicity assays to approve new drugs [21]. In addition, the
FDA recommends genotoxicity testing for all new drugs before carrying out clinical trials and receiving
marketing authorization. The regulatory authorities in most countries have specific guidelines for
testing drug candidates for genotoxicity as part of their safety evaluation [21]. Based on the rapid
development of new nanoproducts, genotoxicity data on MNPs are required for the translation of these
nanoproducts from research laboratories to the clinical market. The physicochemical and biological
properties of nanomaterials are significantly different than their macroscopic counterparts. Decreasing
the size of materials to the nanoscale, extraordinary increases the reactivity and subsequently interaction
of NMs with the biological entities. Moreover, NMs are able to pass through the biological barriers
and exert their beneficial or converse effects [22]. Hence the current safety assessment protocol
applicable for materials in the bulk state must be customized to be applicable for NMs. There are some
critical questions about the suitability of the current regulatory testing regime for NMs, the need for
development of new and customized assessing methods, and the combination of different assessing
method [23]. Figure 3 shows the interface of nature, nanotechnology, and genotoxicity. To the best of
our knowledge, although the genotoxicity of non-biogenic MNPs prepared via conventional physical
and chemical procedures has been discussed, no published work has comprehensively reviewed the
genotoxicity of biologically synthesized MNPs. Therefore, the aim of the current study was to conduct
a global systematic review evaluating the genotoxicity of biogenic MNPs in experimental investigations
that were reported in the literature and involved in vitro and in vivo models.
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2.1. Search Strategy
The genotoxicity of biologically synthesized MNPs was evaluated in a systematic review
carried out by screening literature published online in the following databases; Cochrane, Web
of Science, PubMed, Scopus, Science Direct, ProQuest, and EBSCO. The language was restricted to
English in the literature search, and the published papers were searched from inception to June 30,
2018. The literature was searched by using different combinations of several keywords: ‘synthesis’,
‘biosynthesis’, ‘biofabrication’, ‘green’, ‘bioreduction’, ‘myco*’, ‘biogenic’, ‘Plant*’, ‘phyto*’, ‘herbal*’,
‘fungus mediated’, ‘bacterial mediated’; ‘nanoparticle*’, ‘colloidal’, ‘nanomaterial*’; and ‘genotoxicity’,
‘genotoxic’, ‘DNA fragmentation’, ‘DNA ladder’, ‘DNA damage’.
2.2. Inclusion Criteria
The scientific papers with the following characteristics were included; (1) original papers, (2) papers
contain sufficient information, (3) papers obtained from the aforementioned key search, (4) published
and/or in press papers, (5) English language papers, and (6) the papers that assessed the genotoxicity
of biogenic MNPs through in vitro and/or in vivo models.
2.3. Exclusion Criteria
The papers with the following characteristics were excluded; (1) duplicated papers, (2) letters to
the editor, (3) nonrelated papers, (4) case reports, (5) review papers, (6) congress posters, (7) editorials,
(8) papers written in any language except English, (9) papers without full text, and (10) the papers that
investigated the genotoxicity of chemical and/or physical-mediated fabricated MNPs.
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2.4. Data Collection
The articles were reviewed in detail by two independent reviewers to assess their eligibility for
inclusion. The data extraction form consisted of the first author, publication year, biological source,
NP type, NP size (nm), NP morphology, in vitro model, in vivo model, NP dose, exposure time,
genotoxicity assay, major genotoxicity comments, and genotoxicity (yes or no) (Tables S1 and S2).
3. Results
Figure 4 shows the study design 1profile. The initial database search recovered 900 articles, of
which 246 duplicates were removed. After screening the 654 articles, 404 articles were excluded.
Of the remaining 250 articles, 126 articles were excluded. Searching other sources identified 6
additional articles. Ultimately, 130 articles were included in the current systematic review. Notably,
considerable heterogeneity was found across all studies due to the different natural sources applied for
the preparation of MNPs and the different types of MNPs, as well as the different genotoxicity analysis
methods. The 130 articles included 122 in vitro studies and 8 in vivo studies and applied 153 different
genotoxicity tests: DNA fragmentation assays (n = 58), the comet assay (n = 40), gene expression
methods (n = 19), chromosomal aberration analysis (n = 9), cell cycle analysis (n = 8), the TUNEL
assay (n = 7), micronucleus assays (n = 5), the Ames test (n = 2), and other tests (n = 5). The in vitro
genotoxicity evaluations were carried out with different types of cancerous (n = 35) and normal (n = 9)
cells, bacteria (n = 10), plants (n = 5), plasmids (n = 2), fungi (n = 1), parasites (n = 1), and calf thymus
(n = 1). Most of the genotoxicity studies were carried out on MCF-7 (n = 25) and MDA-MB-231 (n = 9)
cancer cell lines, and normal human lymphocytes were the major normal cell lines used (n = 11). Most
of the genotoxic studies involving bacteria and plants were carried out with Escherichia coli (n = 5) and
Allium cepa (n = 7). The in vivo genotoxicity evaluations were carried out on fish (n = 3), mice (n = 2),
silkworms (n = 1), parasites (n = 1), yeast (n = 1), and marine fleas (n = 1). Phytosynthesis was the
general approach to NP preparation in all studies (n = 88), and fungi were the second most common
resource applied for NP synthesis (n = 18). Bacteria and algae were used to biosynthesize NPs in 16
and 9 studies, respectively. A total of 141 biogenic NPs, including Ag, Au, ZnO, TiO2, Se, Cu, Pt, Zn,
Ag-Au, CdS, Fe3O4, Tb2O3, and Si-Ag NPs, were prepared in the 130 included articles. Notably, AgNPs,
prepared in 68.79% (n = 97) of studies, and AuNPs, prepared in 12.76% (n = 18) of studies, were the two
most predominant biogenic MNPs fabricated in the 130 included articles. Different morphologies of
biogenic MNPs were reported: spherical (n = 76), mostly spherical (n = 19), spherical and other shapes
(n = 18), and other shapes (no spherical) (n = 9). Eight studies reported no morphological data. The
studies also reported different size distributions of NPs: ≤ 25 nm (n = 66), 25–50 nm (n = 46), 50–100 nm
(n = 22), and 100 < nm (n = 5). Notably, 80.57% of studies synthesized biogenic MNPs under 50 nm.
Table S1 provides data on the in vitro genotoxic effects of biogenic NPs for each biological source used
to synthesize MNPs and Table S2 shows the in vivo genotoxicity outcomes. Although several studies
reported no genotoxicity [24–32] or antigenotoxic activity [24,33–36] of biogenic MNPs, most of the
studies reported genotoxic effects at specific concentrations and with a dose or time dependence.
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4. Discussion
4.1. A Mechanistic Approach to Nanogenotoxicity
The rapid development of nanoproducts in recent years has created significant concerns about
their safety. Nanotoxicity as a new branch of toxicity can be described as the study of the adverse
effects of nanomaterials on living organisms and ecosystems [37]. The potential of NPs to contaminate
Medicina 2019, 55, 439 7 of 16
the environment and cause undesirable effects on human life should be clearly addressed before these
nanoproducts reach the clinical market. Genotoxicity is a vital aspect of studying the damage to genetic
information within a cell, such as DNA strand breakages, chromosomal fragmentation, point mutations,
and alterations of gene expression profiles [38]. Nanogenotoxicity can be classified as primary or
secondary. Primary NP-induced genotoxicity can be attributed to the direct or indirect interaction of
NPs with genetic material. During direct primary genotoxicity, NPs directly interact with chromosomes
during interphase and may bind with DNA molecules and prevent DNA replication or transcription.
In addition, NPs could interact with chromosomes during mitosis, causing chromosomal breakage
(clastogenic effect) or loss (aneugenic effect) mechanically or by chemical binding. During indirect
primary genotoxicity, NP-mediated ROS generation and the release of toxic ions from soluble NPs are
indirect interactions that can interfere with proteins essential for DNA replication, transcription, or
repair as well as the mitotic spindle apparatus, centrioles or their associated proteins; these interactions
can inactivate the proteins by structural modifications [39,40]. Figure 5 illustrates the direct and indirect
primary genotoxicity pathways. ROS may cause purine- and pyrimidine-derived oxidized base
lesions, which lead to mispairing in replication; consequently, destructive mutations may occur [41].
In addition, the protein kinases responsible for the regulation of cell cycle events and cell division
may be inactivated by NPs, leading to a disturbance of cell cycle checkpoint functions [42]. Moreover,
the secondary genotoxicity mechanism of NPs is attributed to the excessive generation of ROS by
activated phagocytes, including neutrophils and macrophages, through a chronic in vivo inflammatory
response [39,40]. Figure 6 summarizes the genotoxicity mechanisms of NPs. The genotoxicity of
NPs may be affected by the NP properties, including the composition, size, shape, surface properties,
physicochemical specifications (pH, temperature, etc.), solubility, and other factors such as the NP dose,
exposure time, cell type used, and treatment regime [39,43,44]. The composition of NPs is the main
driving force of the potential genotoxicity, for instance CdSe NPs are strongly toxic, regardless of their
size, shape, and exposure route. Size is another influencing factor of genotoxicity which directly affect
the surface to volume ratio, reactivity, solubility, and the exposure extent of the NPs with biological
entities. Decreasing the size of NPs from the micro to nanoscale significantly increases the surface
to volume ratio and the surface atoms. The increased reactivity results in the higher interaction and
the interference with the biological entities which may induce higher ROS production. Moreover,
the size and the shape of NPs impact the potential of genotoxicity, in the case of dissolved metallic
ions-induced genotoxicity. The surface composition is also a critical parameter which determines types
and the extent of the NP–biological system interaction, the dissolution rate of metallic ions, and the
bio distribution of NPs [45]. Primary genotoxicity is usually evaluated with in vitro models, while
secondary genotoxicity is investigated with in vivo models [39]. This study systematically reviews the
genotoxic potential of biogenic MNPs determined with in vitro and in vivo models using documented
data from a literature review.
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4.2. In Vitro Genotoxicity Studies of Biogenic MNPs
4.2.1. Genotoxicity Studies of Biogenic MNPs against Cancerous and Normal Cell Lines
There are various types of genotoxicity assessment tests available to evaluate the potential
genotoxicity of NPs including: in vitro micronucleus assay (OECD TG 487), DNA assay by agarose
gel electrophoresis, single cell gel electrophoresis assay (SCGE) or Comet assay, the cytokinesis-block
micronucleus cytome (CBMN cyt) assay, Ames test (Bacterial Reversion Mutation Test) (OECD TG 471),
8-hydroxydeoxyguanosine DNA adducts detection, hypoxanthine–guanine hosphoribosyltransferase
(HPRT) forward mutation assay, and g-H2AX staining [46–49]. In vitro genotoxicity assessments of
MNPs have been performed against different cancerous and normal cell lines, including Y79 (human
retinoblastoma), DLA (Dalton’s lymphoma), EAC (Ehrlich’s ascites carcinoma), MDA-MB-231 (human
breast adenocarcinoma), MCF-7 (human breast adenocarcinoma), A549 (human lung adenocarcinoma),
A375 (human malignant melanoma), AMJ-13 (human invasive ductal carcinoma), HeLa (human
cervical cancer), B16-F10 (mouse melanoma), K562 (human leukemic), HT29 (human colorectal
adenocarcinoma), HepG2 (human hepatocellular carcinoma), HCT-15 (human Dukes’ type C, colorectal
adenocarcinoma), U87 (human glioblastoma), PC-3 (human prostate carcinoma), Caov-4 (human
ovarian adenocarcinoma), KB (human carcinoma), MG-63 (human osteosarcoma), Saos-2 (human
osteosarcoma), HT-29 (human colorectal adenocarcinoma), COLO 205 (human Dukes’ type D, colorectal
adenocarcinoma), NCI-H460 (human nonsmall cell lung carcinoma), WEHI-3 (mouse leukemia),
LNCap-FGC (human prostate carcinoma), MDA-MB (human adenocarcinoma mammary gland),
MOLT-4 (human acute lymphoblastic leukemia), T47D (human ductal carcinoma), MCF10-A (human
breast epithelial cell), Hep3B (human hepatocellular carcinoma), Hep2 (human carcinoma), HCT116
(human colorectal carcinoma), HL-60 (acute promyelocytic leukemia), SiHa (human cervical cancer cell),
A431 (human epithelial carcinoma), RAW264.7 (mouse macrophage), ARPE-19 (human retinal pigment
epithelium cell), HaCaT (human keratinocyte), normal human lymphocyte, PBMC (peripheral blood
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mononuclear cell), HEK293 (human embryonic kidney cell), 3T3 (mouse embryo), and V79 (hamster
lung fibroblast). Maity et al., 2018, prepared AgNPs with a size of 3–15 nm by using an ethanolic extract
of Calotropis gigantea latex. At 5.6 µg/mL, the biosynthesized AgNPs induced DNA fragmentation, cell
cycle arrest at the G2/M phase, upregulation of Bax and caspase-3 and downregulation of Bcl-2 [50].
A similar DNA fragmentation result was reported by Reya et al. 2018, who evaluated the DNA damage
of algal-based AgNPs (21–34 nm) at 10–50 µg/mL against the Y79 cell line [51]. Moteriya et al. 2018
investigated the genotoxicity of phytosynthesized AgNPs with an average size of 8 nm against normal
human lymphocytes. No genotoxicity was found up to 50 µg, but fragmented DNA was observed
at 200 µg [52]. Likewise, Moteriya et al. 2017 reported dose-dependent genotoxicity of Caesalpinia
pulcherrima flower-synthesized AgNPs from 2 to 200 µg/mL in normal human lymphocytes. DNA
fragmentation and chromatid gaps in chromosomes were found at 200 µg/mL, and the incidence
of these effects were decreased at lower AgNP concentrations [53]. AgNPs with an average size of
49.98 nm synthesized via a fungus-mediated method caused DNA damage in NCI-H460 cells in a
time-dependent manner at 2–20 µg [54]. Remarkably, several studies reported the nongenotoxicity of
biologically synthesized MNPs. For instance, phytosynthesized CdSNPs with a size of 2–8 nm caused
no DNA damage in normal human lymphocytes at 0.01 µg/mL as evaluated by using a comet assay,
while exposure of normal human lymphocytes to pure commercially procured CdS resulted in extensive
DNA damage [26]. Similarly, Das et al. 2017 reported no genotoxic influence of phytosynthesized
AuNPs on normal human lymphocytes [28]. Phytosynthesized AuNPs at 6–15 µg/mL were also
determined to be nongenotoxic in HaCaT cells using a comet assay [29].
4.2.2. Genotoxicity Studies of Biogenic MNPs against Microbes and Parasites
The genotoxic influences of biogenic MNPs have been also evaluated by using different bacteria,
including Salmonella typhimurium, E. coli, Listeria monocytogenes, Salmonella typhi, Salmonella enterica,
Pseudomonas aeruginosa, Bacillus cereus, Helicobacter pylori, Helicobacter felis, and Staphylococcus aureus; two
plasmids (pZPY112 and pBR322); one fungus (Aspergillus fumigatus); and one parasite (Leishmania
donovani). Lv et al. 2018 reported that at 100 µg/mL, CuNPs with a size range of 6 to 20 nm
synthesized via a bacterially mediated method induced DNA fragmentation in E. coli [55]. In addition,
at 10 mg/mL, AgNPs (10–60 nm) synthesized via a plant-mediated method caused DNA fragmentation
in S. aureus [56]. Similarly, at 1 µg/mL, phytosynthesized AgNPs with an average size of 20 nm
resulted in fragmented DNA in H. pylori and H. felis [57]. In contrast, at concentrations of 1–3 mM,
phytosynthesized AgNPs with sizes of 5–50 nm did not show any genotoxic effects against B. cereus,
S. aureus, L. monocytogenes, S. typhi, or S. enterica [31]. Moreover, at 25 µg/mL, AgNPs synthesized by
a bacterially mediated method caused DNA fragmentation in E. coli; however, no significant DNA
damage was found against S. typhimurium, P. aeruginosa, or S. aureus at the same concentration [58].
The genotoxicity of TiO2 with an average size of 69 nm was investigated in the pBR322 plasmid.
No genotoxicity was found at NP concentrations up to 250 µg/mL, but DNA deformations were
found at 500 µg/mL [59]. Similarly, at 0.51 µg, a significant genotoxic effect of AgNPs with a size of
5 to 40 nm synthesized via a fungus-mediated method was reported for the pZPY112 plasmid [60].
In contrast, at concentrations of 6.25 to 25 µg/mL, phytosynthesized AgNPs with a size of 10 to 15 nm
did not cause DNA damage in the pBR322 plasmid [27]. Notably, Neveen et al. 2013 reported that
at 15 µg/mL, AgNPs with a size of 20 to 140 nm synthesized via an Aspergillus terreus-mediated
method were genotoxic against A. fumigatus according to the comet assay [61]. Additionally, at 50 µM,
phytosynthesized AgNPs with an average size of 35 nm did not cause DNA damage in L. donovani [30].
4.2.3. Genotoxicity Studies of Biogenic MNPs against Plants
The genotoxicity of biogenic MNPs has been evaluated against the following plants; Triticum
aestivum L., Drimia indica, A. cepa, Lathyrus sativus L., and Brassica rapa. Daphedar et al. 2018
investigated the genotoxic effect of ZnNPs with a size of 10–85 nm on the mitotic chromosomes of
root tip meristematic cells in D. indica. The biogenic ZnNPs showed a mitodispersive effect on cell
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division and induced chromosomal abnormalities in a dose- and duration-dependent manner [62]. In
addition, Panda et al. 2017 reported that phytosynthesized ZnONPs with an average size of 48.6 nm
significantly induced DNA damage in a dose-dependent manner in L. sativus L., with maximum
genotoxicity observed at 100 mg/L [63]. Abdelsalam et al. 2018 investigated the genotoxicity of
AgNPs synthesized by an algally-mediated method at concentrations of 10 to 50 ppm on T. aestivum L.
root tip cells. The AgNPs produced various types of chromosomal aberrations, such as an incorrect
orientation at metaphase, chromosomal breakage, metaphasic plate distortion, spindle dysfunction,
and stickiness [64]. Additionally, a study investigated the genotoxicity of AgNPs (average size of
20 nm) at concentrations of 5 to 20 µg/mL in mitotic and meiotic cells of A. cepa. Various chromosomal
aberrations were observed even at low concentrations of AgNPs [65]. Similarly, AgNPs with sizes
of 2 to 11 nm synthesized by a bacterially mediated method were studied for their genotoxic effect
at concentrations of 1 to 10 mg/mL on B. rapa. ssp. rapa L. The AgNPs produced extensive DNA
damage and altered the expression of genes involved in a variety of metabolic pathways as well as the
inhibition of chlorophyll and anthocyanin biosynthesis and an overproduction of ROS [66].
4.3. In Vivo Genotoxicity Studies of Biogenic MNPs
In vivo investigations have been carried out on Saccharomyces cerevisiae (yeast), Bombyx mori
(silkworm) larvae, Cyprinus carpio (fish) blood, Poecilia reticulata (fish) larvae, Ceriodaphnia cornuta
(marine flea) adults, Danio rerio (zebrafish), Leishmania major (parasite) promastigotes, and mice bearing
DAL tumor cells. Biogenic AgNPs at concentrations of 50 and 100 µg/mL caused significant DNA
damage in S. cerevisiae, while insignificant DNA damage was observed at 12.5 and 25 µg/mL [67].
In addition, at 100 ppm, biogenic AgNPs induced significant DNA fragmentation in larvae of the
mulberry silkworm B. mori [68]. AgNPs at 40 µg/mL led to remarkable DNA damage in adults
of the microcrustacean C. cornuta, whereas in larvae of P. reticulata, 20 µg/mL AgNPs led to DNA
damage [69]. Notably, AgNPs produced micronuclei and nuclear abnormalities such as blebbed
nuclei, lobed nuclei, and notched nuclei in peripheral blood cells of zebrafish (D. rerio), indicating
genotoxicity [70]. Moreover, phytosynthesized AgNPs fragmented DNA into approximately 100–150 bp
pieces in DAL-induced tumor cells in mice bearing the DAL tumor model, suggesting mitochondrially
mediated apoptosis in DAL cell lines [71].
4.4. Antigenotoxicity Studies of Biogenic MNPs
Sarac et al. 2018 investigated the antimutagenic activity of biogenic AgNPs at 250, 100 and
50 µg/plate in S. typhimurium TA98 and TA100 against 4-nitro-o-phenylenediamine (4-NPD: 3 µg/plate)
and sodium azide (NaN3: 8 µg/plate) using the Ames test. The AgNPs had an effective antimutagenic
effect at all tested concentrations on TA98 cells and at 250 and 100 µg/plate on TA100 cells [24].
Another study investigated antigenotoxic effect of TiO2NPs biosynthesized from Turbinaria conoidesv
by an algally-mediated method. Genotoxicity studies were conducted for screening of Mutagenicity
using Ames test, to prove this as an antigenotoxicant. TiO2NPs biosynthesized were evaluated for
antigenotoxicity against Mitomycin C-induced genetic toxicity in human peripheral lymphocytes. It is
well known that administration of Mytomycin C causes increased cell damage, which in turn leads
to increased chromosome aberration wherein co-administration of TiO2NPs along with Mytomycin
C reduced the frequency of Chromosome aberration and Ames test. Thus it was inferred from the
present study that the TiO2NPs biosynthesized using Turbinaria conoides can be used as an efficient
and potent drug owing of its antigenotoxicity and antimutagenicity property [33]. Moreover, a study
reported the antigenotoxic effect of green-synthesized AgNPs from Ocimum sanctum leaf extract against
cyclophosphamide (CP)-induced genotoxicity in normal human lymphocytes. CP administration to
human lymphocytes culture caused reduction in mitotic index (MI) and increase in chromosomal
damages. The AgNPs at concentrations of 50 to 200 µg/mL reduced the chromosomal damage caused
by CP and there was an increase in MI. The biological way of synthesizing AgNPs has advantages like
cost effectiveness and ecofriendly. Also, the bio-synthesized AgNPs of O. sanctum leaf extract was
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found to be a powerful genoprotective agent [34]. An aqueous leaf extract of lemon plant was used as
a precursor for synthesis of colloidal SeNPs. MTT assay as well single cell gel electrophoresis assay or
comet assay revealed that application of phytosynthesized SeNPs at 0.01 µg/µL resulted in less cell
death of normal human lymphocytes and prevented DNA damage when cells were exposed to UVB
radiation. The fluorescent property of SeNPs can be used as diagnostic agent. Further, their anti DNA
damaging property can be investigated as a chemotherapeutic agent in cancer therapy [36]. In a similar
study, phytosynthesized SeNPs from Terminalia arjuna leaf extract prevented the genotoxic effect of
arsenite on normal human lymphocytes. Studies on cell viability using MTT assay and DNA damage
using comet assay revealed that synthesized SeNPs at 0.01 µg/µL showed a promising chemoprotective
effect against arsenite-induced cell death and DNA damage, respectively [35].
5. Conclusions
The present study systematically reviewed laboratory studies that evaluated the genotoxicity of
biogenic MNPs by using in vitro and in vivo models. It was shown that MNPs could be synthesized
using different biological sources, including plants, microorganisms, and even algae, in various shapes
and sizes. Although several studies reported the antigenotoxic influence of biogenic MNPs, most
studies demonstrated their genotoxicity. Performing genotoxicity studies with MNPs to identify
their potential damage is immensely important. In the past decade, a large number of papers
have reported green synthesis methods for MNPs that utilize biological pathways as an ecofriendly
approach. However, laboratory studies on the genotoxicity of biologically synthesized MNPs are
still scarce and exhibit significant heterogeneity. Hence, comparing and drawing conclusions from
genotoxicity data is quite difficult. However, the results of this study emphasized that the biosynthesis
of MNPs using natural products may not prevent MNP genotoxicity. A better understanding of
the genotoxicity mechanisms of biogenic MNPs would enable us to prevent potential damage. The
underlying genotoxicity mechanism of chemically synthesized NP have been discussed in the other
review paper and the current review provides a valuable summary of the genotoxicity information
on biologically synthesized MNPs reported in the literature from inception to June 30, 2018. Further
well-designed genotoxicity studies using the same protocol are required to clearly address not only
the factors affecting the genotoxicity of biogenic MNPs but also the mechanisms of MNP genotoxicity,
with a particular need for more in vivo studies.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1010-660X/55/8/439/s1.
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